nach oben

Clinical Rheumatology

Erschienen in:

01.07.2010 | Review Article

Off-label use of rituximab in systemic lupus erythematosus: a systematic review

verfasst von: Eleanor Murray, Martin Perry

Erschienen in: Clinical Rheumatology | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.

Grammer AC, Lipsky PE (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5(Suppl 4):S22–S27CrossRefPubMed

Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R (1999) High disease activity at baseline does not prevent a remission in patients with systematic lupus erythematosus. Rheumatology 38:724–727CrossRefPubMed

Danchenko N, Satia J, Anthony M (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318CrossRefPubMed

Kasitanon N, Magder L, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine 85(3):147–156CrossRefPubMed

Hoyer BF, Moser K, Hauser AE et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199:1577–1584CrossRefPubMed

SIGN 50: A guideline developer’s handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html

Clark EA, Ledbetter JA (2005) How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 64(suppl 4):iv77–80CrossRefPubMed

Gong Q, Ou Q, Ye S et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817–826PubMed

Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J et al (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48(2):455–9CrossRefPubMed

10.

Barnard J, Palanichamy A, Bauer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA

11.

Chan O, Madaio MP, Shlomchik MJ (1999) B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol 163:3592–3596PubMed

12.

Chan OTM, Hannum LG, Haberman AM et al (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189:1639–1648CrossRefPubMed

13.

Looney R, Anolik J, Campbell D, Felgar R, Young F, Arend L, Sloand J, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus. A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580–2589CrossRefPubMed

14.

Martin F, Chan AC (2006) B cell Immunology in disease: evolving concepts from the clinic. Annual Rev Immunol 24:467–96CrossRef

15.

Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8(3):R83CrossRefPubMed

16.

Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ et al (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580–90CrossRefPubMed

17.

Anolik J, Barnard J, Owen T, Zheng B, Kemshetti S, Looney R, Sanz I (2007) Delayed memeory B cell recovery in peripheral blood and lymphoid tissue in systematic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044–3056CrossRefPubMed

18.

Gillis J, Dall’era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57(3):538–542CrossRefPubMed

19.

Tamimoto Y, Horiuchi T, Tsukamoto H et al (2008) A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology 47:821–827CrossRefPubMed

20.

Jonsdottir T, Gunnarsson I, Risselada A et al (2008) Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67(3):330–334CrossRefPubMed

21.

Reynolds A, Toescu V, Yee C (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18(1):67–73CrossRefPubMed

22.

Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–81CrossRefPubMed

23.

Bootsma H, Spronk P, Derksen RH et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–9CrossRefPubMed

24.

Lu TY-T, Ng KP, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M, Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487CrossRefPubMed

25.

Lindholm C, Börjesson-Asp K (2008) Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Rheumatol 35(5):826–33

26.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang D, the Committee on Prognosis Studies in SLE (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–40CrossRefPubMed

27.

Hay E, Bacon P, Gordon C, Isenberg D, Maddison P, Snaith M et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 86:447–58PubMed

28.

Karim MY, Alba P, Cuadrado M-J, Abbs IC, D’Cruz DP, Khamashta MA, Hughes GRV (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876–882CrossRefPubMed

29.

K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3): 253.LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787.aspx. Sourced 24/05/09

30.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract L12

31.

Smith K, Jones R, Burns S et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and retreatment. Arthritis Rheum 54(9):2970–82CrossRefPubMed

32.

Perry ME, Lavelle C, Maguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: ‘real life’ experience of the first 40 patients. Scottish Medical Journal (in press)

33.

Weide R, Heymanns J, Pandorf A, Köppler H (2003) Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12:779–782CrossRefPubMed

34.

Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T (2007) A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17:191–197CrossRefPubMed

35.

Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney R, Luning Prak E, Kimberly R, Zhang Y, Eisenberg R (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Disease 67:1724–1731CrossRef

36.

Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstract 441

37.

Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson S, Henriksson E, van Vollenhoven R (2007) Histopathological and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56(4):1263–1272CrossRefPubMed

38.

Tokunaga M, Saito K, Kawabata D et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470–475CrossRefPubMed

39.

Galarza C, Valencia D, Tobón G, Zurita L, Mantilla R, Pineda-Tamayo R, Rojas-Villarraga A, Rueda J, Anaya J (2008) Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clinic Rev Allerg Immunol 34:124–128CrossRef

40.

Mohd Shahrir MS, Abdul Halim AG, Soehardy Z, Norella Kong CT (2007) Clinical experience in using CD20 monoclonal antibody in treating severe systemic lupus erythematosus. APLAR J Rheumatol 10:112–116CrossRef

41.

Heidel F, Lipka D, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97(2):228–33PubMed

42.

Sfikakis PP, Boletis JN, Lionaki S et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501–513CrossRefPubMed

43.

Ceccarelli F, Perricone C, Massaro L et al (2009) Good safety profile of repeated b cell depletion therapy in patients with refractory systemic lupus erythematosus. Ann Rheum Dis 68(Suppl3):248

44.

Mohrbacher A (2005) B cell non-Hodgkin’s lymphoma: rituximab safety experience. Arthritis Res Ther 7(Suppl 3):S19–S25CrossRefPubMed

45.

Genentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/03/11/46787.aspx

46.

Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC (2009) Is combination rituximab with cyclophosphamide better than rituximab alone in treatment of lupus nephritis? Rheumatology (Oxford) 48:892–8CrossRef

47.

Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct 2008

48.

Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R et al (2002) The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46:1554–62CrossRefPubMed

49.

Tokunaga M, Fujii K, Saito K et al (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44(2):176–182CrossRefPubMed

50.

Gordon C et al (2009) EULAR points to consider in conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 68:470–6CrossRefPubMed

51.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P (2000) Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 9:322–7CrossRefPubMed

52.

Lavie F, Miceli-Richard C, Ittah M et al (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66(5):700–3CrossRefPubMed

53.

Gottenberg J, Guillevin L, Lambotte O et al (2005) Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913–920CrossRefPubMed

54.

Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP (2009) Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 24(7):2157–60CrossRefPubMed

55.

Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, Nov 4–9 2008, SA-PO2960

56.

García Hernández FJ, Ocaña Medina C, González León R, Garrido Rasco R, Colorado Bonilla R, Castillo Palma MJ, Sánchez Román J (2007) Rituximab for treatment of patients with systemic autoimmune diseases. Med Clin (Barc) 128(12):458–62CrossRef

57.

Karpouzas G, Gogia M, Moran R, Cooray D (2009) Rituximab therapy induces durable remissions in patients with refractory systemic lupus erythematosus (SLE). Ann Rheum Dis 68(Suppl3):248

58.

Melander C et al (2009) Rituximab in severelupus nephritis: early B cell depletion affects long-term renal outcome. Clinical Journal of American Society of Nephrology 4:579–587CrossRef

59.

Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24:3717–23CrossRefPubMed

Titel: Off-label use of rituximab in systemic lupus erythematosus: a systematic review
verfasst von: Eleanor Murray
Martin Perry
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 7/2010
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1387-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Off-label use of rituximab in systemic lupus erythematosus: a systematic review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

Renal cortical necrosis at presentation in a patient with systemic lupus erythematosus: an autopsy case report

Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis

Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

Diffuse systemic sclerosis and autoimmune hepatitis: a unique association

Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab

A case of Hughes–Stovin syndrome associated with hyperhomocysteinemia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin